Comunicati stampa

SAN RAMON, Calif. –  February 18, 2020 – BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced that Gregg Stone, MD, of New York’s Mount Sinai Health System has signed on to the pivotal ALIVE Trial of the Revivent TC™ TransCatheter Ventricular Enhancement System as co-principal investigator.


 

San Ramon, CA – February 6, 2020 – Bioventrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the highest priority reimbursement in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System by achieving the NUB Status 1 designation from InEk, the German Institute for Hospital Remuneration.


San Ramon, CA, Nov. 19, 2019 -- BioVentrix, Inc., a privately-held company with a first-in-class, transcatheter-based structural heart device to treat heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation status for its Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure.


Image

BioVentrix è una società privata di dispositivi medici con sede a San Ramon, in California, negli Stati Uniti.

Le nostre notizie

Contattaci

© 2020 BioVentrix. Tutti i diritti riservati. Realizzato da MedTech Momentum
Il marchio Revivent TC ™ è un marchio registrato a livello federale di proprietà di BioVentrix. Qualsiasi utilizzo non autorizzato è espressamente vietato.